Cargando…
In vivo administration of BL-3050: highly stable engineered PON1-HDL complexes
BACKGROUND: Serum paraoxonase (PON1) is a high density lipoprotein (HDL)-associated enzyme involved in organophosphate (OP) degradation and prevention of atherosclerosis. PON1 comprises a potential candidate for in vivo therapeutics, as an anti-atherogenic agent, and for detoxification of pesticides...
Autores principales: | Gaidukov, Leonid, Bar, Dganit, Yacobson, Shiri, Naftali, Esmira, Kaufman, Olga, Tabakman, Rinat, Tawfik, Dan S, Levy-Nissenbaum, Etgar |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2785756/ https://www.ncbi.nlm.nih.gov/pubmed/19922610 http://dx.doi.org/10.1186/1472-6904-9-18 |
Ejemplares similares
-
PON-1 carbamylation is enhanced in HDL of uremia patients
por: Chang, Chiz-Tzung, et al.
Publicado: (2018) -
BL-7010 Demonstrates Specific Binding to Gliadin and Reduces Gluten-Associated Pathology in a Chronic Mouse Model of Gliadin Sensitivity
por: McCarville, Justin L., et al.
Publicado: (2014) -
Assessment of a 3050/3200 nm fiber laser system for ablative fractional laser treatments in dermatology
por: Wang‐Evers, Michael, et al.
Publicado: (2022) -
Reactive Dicarbonyl Scavenging Effectively Reduces MPO-Mediated Oxidation of HDL and Restores PON1 Activity
por: Huang, Jiansheng, et al.
Publicado: (2020) -
Quantifying PON1 on HDL with nanoparticle-gated electrokinetic membrane sensor for accurate cardiovascular risk assessment
por: Kumar, Sonu, et al.
Publicado: (2023)